A Single-blind, Multi-center, Randomized, Active-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Immunogenicity of Intramuscular Three Injections With LBVE(Multivalent Pneumococcal Conjugate Vaccine) Compared to Prevnar13 in Healthy Infants
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs LBVE 013 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors LG Chem
- 04 Oct 2018 Planned End Date changed from 1 Mar 2019 to 30 Mar 2019.
- 04 Oct 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 20 Mar 2018 New trial record